source
- FDA places Bright Minds seizure drug BMB-101 on partial hold over mouse toxicity, shares plungeThe U.S. Food and Drug Administration issued a partial clinical hold on BMB-101, an experimental seizure treatment from Bright Minds Biosciences, after regulators identified toxicity concerns in pr…
- FDA accepts first Keytruda biosimilar application as Merck faces looming patent cliffThe U.S. Food and Drug Administration has accepted the first publicly announced filing for a Keytruda biosimilar, identified as FYB206, which could receive approval as early as the third quarter of…